总结了细胞表面受体的新命运，即细胞核中的裂解激活。细胞表面受体的胞内结构域（ICD）被γ-分泌酶等酶裂解，易位至细胞核，形成参与肿瘤发生和发展的转录复合物。这种命运具有临床意义，因为裂解酶抑制剂已显示出通过减少致瘤性 ICD 来治疗晚期肿瘤的有效性。此外，合成受体的构建也符合命运机制。这篇综述详细介绍了细胞核中裂解激活的每个步骤，阐明了致瘤机制，探索了抗肿瘤治疗中的应用，并仔细研究了可能的局限性。版权所有 © 2024 Elsevier Ltd. 保留所有权利。

A new fate of cell surface receptors, cleaved activation in the nucleus, is summarized. The intracellular domain (ICD) of cell surface receptors, cleaved by enzymes like γ-secretase, translocates to the nucleus to form transcriptional complexes participating in the onset and development of tumors. The fate is clinically significant, as inhibitors of cleavage enzymes have shown effectiveness in treating advanced tumors by reducing tumorigenic ICDs. Additionally, the construction of synthetic receptors also conforms with the fate mechanism. This review details each step of cleaved activation in the nucleus, elucidates tumorigenic mechanisms, explores application in antitumor therapy, and scrutinizes possible limitations.Copyright © 2024 Elsevier Ltd. All rights reserved.